Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launch
read at Endpoints ↗DealPositive
Apnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering.
The capital will be used to advance its lead drug candidate, with plans to begin a launch in 2027 pending regulatory approval.
The IPO comes after more than three years of preparation for a Nasdaq listing, reflecting investor interest in the sleep-disorder market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch”
read at Endpoints ↗83 words · retrieved Jul 31
comments(0)
5-min edit window · permanent after that